AstraZeneca PLC (AZN)vsZEN Graphene Solutions Ltd (ZTEK)
AZN
AstraZeneca PLC
$188.41
+1.47%
HEALTHCARE · Cap: $284.30B
ZTEK
ZEN Graphene Solutions Ltd
$0.49
-1.91%
HEALTHCARE · Cap: $51.37M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 6409941% more annual revenue ($60.44B vs $942,880). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
ZTEK
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$188.41
$6.16 discount
Margin of Safety
+86.9%
Fair Value
$4.99
Current Price
$0.49
$4.50 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 73.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -65.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : ZTEK
The strongest argument for ZTEK centers on Revenue Growth, Debt/Equity. Revenue growth of 73.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : ZTEK
The primary concerns for ZTEK are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while ZTEK is a hypergrowth play — different risk/reward profiles.
ZTEK carries more volatility with a beta of 0.32 — expect wider price swings.
ZTEK is growing revenue faster at 73.1% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 23/100), backed by strong 17.2% margins and 12.5% revenue growth. ZTEK offers better value entry with a 86.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
ZEN Graphene Solutions Ltd
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ZEN Graphene Solutions Ltd (ZTEK) is an innovative leader in the materials technology sector, specializing in the extraction and commercialization of high-purity graphene derived from natural graphite. Through its proprietary techniques, ZTEK is poised to impact numerous industries, including energy storage, environmental remediation, and advanced manufacturing, offering cutting-edge graphene solutions. The company’s strategic focus on sustainability, underpinned by significant research and development initiatives, enhances its competitive edge in the rapidly expanding graphene market. As ZTEK leverages emerging opportunities and continues to advance its technological capabilities, it is well-positioned to deliver substantial long-term value for investors in the context of rising global demand for innovative and advanced materials.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?